Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | recruiting | Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 13 | Sep 16, 2026 | clinicaltrials |
| NCT04165772 | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | recruiting | Phase 2 | 212 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT05898399 | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA) | recruiting | Phase 1 / Phase 2 | 181 | Artios Pharma LtdINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07165132 | Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs. | recruiting | Phase 1 | 104 | RayzeBio, Inc.INDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | recruiting | Phase 1 | 280 | Incyte CorporationINDUSTRY | 5 | Sep 15, 2026 | clinicaltrials |
| NCT07532018 | DXP-106 in Solid Tumor Patients.(DXP-106) | recruiting | Phase 1 | 54 | Singlomics Biopharmaceuticals Zhuhai Co., Ltd.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02464696 | Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure | recruiting | N/A | 256 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04984551 | Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia | recruiting | Phase 2 | 312 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05067283 | A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)(KANDLELIT-001) | recruiting | Phase 1 | 830 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Sep 14, 2026 | clinicaltrials |
| NCT05430373 | GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors | recruiting | Phase 1 | 31 | Grit BiotechnologyINDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05691608 | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2(MAPPYACTS2) | recruiting | N/A | 1,800 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06134960 | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor | recruiting | Phase 1 | 12 | Peking UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06192875 | A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study) | recruiting | — | 10,000 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06589596 | An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 525 | BeOne MedicinesINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT06596473 | A Study of BG-C477 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 310 | BeOne MedicinesINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06046742 | A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06292845 | Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents(SprayDye) | recruiting | N/A | 200 | Erasmus Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06598800 | Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 153 | BeOne MedicinesINDUSTRY | 4 | Sep 11, 2026 | clinicaltrials |
| NCT06657222 | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 5 | Sep 11, 2026 | clinicaltrials |
| NCT07225088 | DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Cancer | recruiting | N/A | 125 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07278739 | Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams | recruiting | N/A | 1,020 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07586943 | SKB118 Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 530 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07719920 | A Phase Ia/Ib Study of HW221043 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 99 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07746141 | A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations | recruiting | Phase 1 | 100 | BeOne MedicinesINDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT04471987 | Safety and Early Signs of Efficacy of IL12-L19L19.(DODEKA) | recruiting | Phase 1 | 80 | Philogen S.p.A.INDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | recruiting | Phase 1 | 101 | Kyowa Kirin Co., Ltd.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06279013 | Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment(SYMON) | recruiting | N/A | 600 | NRG OncologyOTHER | 2 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT06826313 | A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 12 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07231211 | A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 258 | Shanghai Shengdi Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07356453 | A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 40 | FoRx Therapeutics AGINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | recruiting | Phase 1 | 103 | GenmabINDUSTRY | 3 | Sep 10, 2026 | clinicaltrials |
| NCT07753226 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 39 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07813000 | Physician and Patient Preferences for Cell Therapies in Advanced Solid Tumors | recruiting | — | 1,020 | Zhejiang UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT03907475 | Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial | recruiting | Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06150885 | A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors(CAR001) | recruiting | Phase 1 / Phase 2 | 60 | Ever Supreme Bio Technology Co., Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06578624 | Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 70 | Lamassu Bio IncINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06597721 | ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | recruiting | Phase 1 | 210 | Adcendo ApSINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 392 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | BioNTech SEINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07166601 | M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors(TITER) | recruiting | Phase 1 | 77 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 121 | GenmabINDUSTRY | 2 | Sep 9, 2026 | clinicaltrials |
| NCT07436728 | A Study of TAK-505 in Adults With Solid Tumors | recruiting | Phase 1 / Phase 2 | 151 | TakedaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07695831 | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors | recruiting | Phase 1 | 112 | GenmabINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07703163 | Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer(SGLT2SOLID) | recruiting | Phase 1 | 15 | West China HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811037 | A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, Immunogenicity, and Preliminary Efficacy of SGT003 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 332 | Beijing Sungen Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
Data updated 14 days agoSource updated Sep 16, 2026source: clinicaltrials